To print: Select File and then Print from your browser's menu

Title: Metformin Shows Promise for Diabetes Prevention, but Further Studies Needed

URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&dopt=Abstract&list_uids=15150378

Ann Pharmacother 2004 Jul;38(7):1283-1285. Epub 2004 May 18 "Metformin for Prevention of Type 2 Diabetes"
06/24/2004 11:05:00 AM
By Keely S. Solomon, Ph.D.

Metformin may help prevent type 2 diabetes in individuals at high risk of developing the disease, but new studies must evaluate its long-term safety, efficacy, cost-effectiveness, according to Donald L. Sullivan, PhD, RPh, and Aleda M. Hess, Pharm D, both of Ohio Northern University, Ada, United States. Metformin targets insulin resistance by increasing the sensitivity of insulin receptors in muscle tissue, and it is also known to decrease hepatic glucose production. Some researchers have hypothesised that the drug may help prevent type 2 diabetes. To address this hypothesis, Dr. Sullivan and colleagues identified and evaluated studies that have examined the effect of metformin on diabetes prevention. Their search identified three relevant studies. The earliest study (Fontfonne et al. [Diabetes Care 1996) examined the efficacy of metformin in preventing insulin resistance syndrome in 324 adults with upper body obesity. After 1 year of treatment, patients receiving metformin experienced a significantly lower increase in fasting blood glucose levels compared with the placebo group (3.6 mg/dL vs. 7.2 mg/dL, P < .05). "These results are limited, yet showed the need for a larger clinical study to prove metformin's preventative effects," Drs. Sullivan and Hess write. A second study examined the effects of metformin in preventing type 2 diabetes in 29 adolescent who had pre-existing factors of this disease (Freemark et al. Pediatrics 2001). After 6 months of treatment, patients receiving metformin showed a significant decline in fasting blood glucose levels (84.9 to 75.1 mg/dL, P < .02) and a 0.5 kg/m² decrease in body mass index (BMI), whereas the placebo group showed no change in fasting blood glucose and a 0.9 kg/m² increase in BMI. However, the authors note that the study was limited by its small sample size and short duration. The largest study identified in the search was reported by the Diabetes Prevention Program Research Group (N Engl J Med 2002 Feb 7;346(6):393-403). The study randomised 3234 individuals who were considered to be at risk of developing diabetes into 3 treatment categories: 1) metformin 850 mg twice daily and diet and exercise recommendations, 2) placebo twice daily and lifestyle recommendations, and 3) lifestyle recommendations only. After 2.8 years of therapy, incidence of type 2 diabetes was 58% lower in the group with radical lifestyle changes only and 31% lower in the metformin group compared with the placebo group. Taken together, Drs. Sullivan and Hess propose that the studies show some potential for metformin in the treatment of the prediabetic condition. Although exercise may be a more effective prevention method, he suggests that the drug could potentially serve as an alternative choice for patients who are unwilling to commit to or maintain radical lifestyle changes. They caution, however, that long-term data from a larger population are needed before advocating the use of metformin in this capacity.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&dopt=Abstract&list_uids=15150378

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.